EUVIMEDEUVIMED entdecken
Klinische Studie (Phase II)Klinische Studie (Phase III)Multizentrische StudieRandomisierte kontrollierte Studie

Neoadjuvant chemoradiation with or without PD-1 blockade in locally advanced rectal cancer: a randomized phase 2 trial

Yingchi Yang, Kai Pang, Guole Lin, Xinzhi Liu, Jiale Gao, Jiaolin Zhou, Lai Xu, Zhidong Gao, Yingchao Wu, Ang Li, Jiagang Han, Guoju Wu und 11 weitere

Nature Medicine · 2025-02 · 31 (2) · 449-456

DOI: 10.1038/s41591-024-03360-5 ↗

Kurz gefasst

Klinische Studie (Phase II) in der Zeitschrift Nature Medicine, online erschienen am 06.01.2025. Verfasst von Yingchi Yang und 22 weiteren Autor:innen. Beteiligte Einrichtung: Department of General Surgery, Beijing Friendship Hospital, Capital Medical University, Beijing, China. Hauptthemen laut MEDLINE: Chemoradiotherapy, Immune Checkpoint Inhibitors, Neoadjuvant Therapy, Programmed Cell Death 1 Receptor. Die Arbeit wurde bisher 54-mal zitiert (Crossref) und nennt 38 Literaturangaben. Gefördert von: Beijing Postdoctoral Research Foundation, Beijing Li Huanying Medical Foundation, BeiGene, Ltd., and National Key Technologies R&D Program.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Radiotherapy displays unique antitumor synergism with immune checkpoint inhibitors, which is indicated by high pathological complete response (pCR) rates from single-arm trials of locally advanced rectal cancer (LARC). Here we test the efficacy and safety of the radiation-immune checkpoint inhibitor combination in patients with LARC in a phase 2, randomized trial conducted in eight major colorectal cancer centers in Beijing. In total, 186 eligible all-comer (proficient mismatch repair and deficient mismatch repair) participants were enrolled. The patients were randomly assigned to receive neoadjuvant chemoradiation + concurrent/sequential PD-1 blockade (experiment groups A/B) or neoadjuvant chemoradiation alone (control group). Radical surgeries were scheduled after neoadjuvant treatments. The primary endpoint was the pCR rate. The pCR rates were 27.1%, 32.7% and 14.0% for experiment groups A and B and the control group, respectively. The difference in pCR rates between experiment group B and the control group reached statistical significance (risk ratio 2.332, 95% confidence interval 1.106-4.916; P = 0.019). No substantial differences between either one of the experiment groups and the control group were observed regarding adverse reaction, surgical complication and disease progression. Our results show that adding PD-1 blockade after neoadjuvant chemoradiation increases the pCR rate for patients with LARC and raises no substantial safety concerns. Phase 3 trials with larger sample sizes are warranted (ClinicalTrials.gov identifier NCT05245474 ).

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ChemoradiotherapyImmune Checkpoint InhibitorsNeoadjuvant TherapyProgrammed Cell Death 1 ReceptorRectal NeoplasmsAdultAgedFemaleHumansMaleMiddle AgedTreatment Outcome

Substanzen

Immune Checkpoint InhibitorsPDCD1 protein, humanProgrammed Cell Death 1 Receptor

Autor:innen und Institutionen

  • Department of General Surgery, Beijing Friendship Hospital, Capital Medical University, Beijing, China.
  • Department of General Surgery, Peking Union Medical College Hospital, Beijing, China.
  • Gastrointestinal Cancer Center, Unit III, Peking University Cancer Hospital and Institute, Beijing, China.
  • Department of Gastroenterological Surgery, Peking University People's Hospital, Beijing, China.
  • Department of General Surgery, Peking University First Hospital, Beijing, China.
  • Department of General Surgery, Xuanwu Hospital, Capital Medical University, Beijing, China.

Förderung

  • Beijing Postdoctoral Research Foundation
  • Beijing Li Huanying Medical Foundation, BeiGene, Ltd., and National Key Technologies R&D Program

Zitieren

APA

Yang, Y., Pang, K., Lin, G., Liu, X., Gao, J., Zhou, J., Xu, L., Gao, Z., Wu, Y., Li, A., Han, J., Wu, G., Wang, X., Li, F., Ye, Y., Zhang, J., Chen, G., Wang, H., Kong, Y., …, & Zhang, Z. (2025). Neoadjuvant chemoradiation with or without PD-1 blockade in locally advanced rectal cancer: a randomized phase 2 trial. Nature Medicine, 31(2), 449-456. https://doi.org/10.1038/s41591-024-03360-5

Vancouver

Yang Y, Pang K, Lin G, Liu X, Gao J, Zhou J, et al. Neoadjuvant chemoradiation with or without PD-1 blockade in locally advanced rectal cancer: a randomized phase 2 trial. Nature Medicine. 2025;31(2):449-456. doi:10.1038/s41591-024-03360-5

BibTeX
@article{Yang2025,
  author = {Yang, Yingchi and Pang, Kai and Lin, Guole and Liu, Xinzhi and Gao, Jiale and Zhou, Jiaolin and Xu, Lai and Gao, Zhidong and Wu, Yingchao and Li, Ang and Han, Jiagang and Wu, Guoju and Wang, Xin and Li, Fei and Ye, Yingjiang and Zhang, Jie and Chen, Guangyong and Wang, Hao and Kong, Yuanyuan and Wu, Aiwen and Xiao, Yi and Yao, Hongwei and Zhang, Zhongtao},
  title = {Neoadjuvant chemoradiation with or without PD-1 blockade in locally advanced rectal cancer: a randomized phase 2 trial},
  journal = {Nature Medicine},
  year = {2025},
  volume = {31},
  number = {2},
  pages = {449--456},
  doi = {10.1038/s41591-024-03360-5}
}
Kostenlos starten →